A Clinical Study of Alopecia Areata and the Efficacy of 0.03% Topical Tacrolimus in Its Treatment

The study evaluated the efficacy of 0.03% topical tacrolimus in treating alopecia areata in 50 patients (33 males and 17 females) over a 12-week period. Results showed that 40% of patients with scalp involvement, 10% with facial involvement, and 4% each with eyebrow and moustache involvement had a good response, while 16% with scalp and 10% with facial involvement had an excellent response. No cutaneous or systemic side effects were observed. The study concluded that topical tacrolimus is effective for treating alopecia areata, with potential for better results at higher strengths (0.1%), and is particularly suitable for children due to its non-irritant nature and absence of side effects.